Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederclinicaltrials.gov
ClinicalTrials.gov: Olutasidenib | Last update posted in the last 14 days
Get the latest updates from ClinicalTrials.gov: Olutasidenib | Last update posted in the last 14 days directly as they happen.
Follow now < 10 followers
Latest posts
Last updated 1 day ago
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
3 days ago
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome Interventions: Procedure: Allogeneic Hematopoietic Stem Cell...
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
9 days ago
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome Interventions: Procedure: Allogeneic Hematopoietic Stem Cell...
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
11 days ago
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome Interventions: Procedure: Biospecimen Collection; Procedure: Bone...
A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
15 days ago
Conditions: Myeloid Malignancies Interventions: Drug: Olutasidenib Sponsors: M.D. Anderson Cancer Center Recruiting
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
16 days ago
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome Interventions: Procedure: Allogeneic Hematopoietic Stem Cell...
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
17 days ago
Conditions: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Clonal Cytopenia of Undetermined Significance Interventions...
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
19 days ago
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome Interventions: Procedure: Allogeneic Hematopoietic Stem Cell...
Testing the Addition of an IDH1 Inhibitor, Olutasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH1 Mutation (A MyeloMATCH Treatment Trial)
23 days ago
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome Interventions: Procedure: Biospecimen Collection; Procedure: Bone...
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
about 1 month ago
Conditions: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Clonal Cytopenia of Undetermined Significance Interventions...
Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
about 1 month ago
Conditions: Acute Myeloid Leukemia Interventions: Drug: Olutasidenib Investigational Agent Administration Sponsors: Virginia...
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
about 1 month ago
Conditions: Acute Myeloid Leukemia; IDH1 Mutation Interventions: Drug: Olutasidenib; Drug: Venetoclax; Drug...
A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
about 2 months ago
Conditions: Myeloid Malignancies Interventions: Drug: Olutasidenib Sponsors: M.D. Anderson Cancer Center Recruiting